

Produced by MJBizScience

RADICLE SCIENCE Democratizing clinical trials to transform health & wellness products into democratized precision solutions


THE EMERALD CONFERENCE Produced by MJBizScience

Jeff Chen, MD, MBA

Physician, Scientist, Entrepreneur, Founder and former Exec Director of UCLA Cannabis Research Initiative (one of world's first), Editor at Healthline Media (86M visitors/month), U.S. patent holder

Pelin Thorogood, M.Eng, MBA

Tech CEO, Big Data & Analytics Expert, Entrepreneur, Philanthropist, Trustee & Treasurer of UC San Diego Foundation, Co-Founder & President of Wholistic Foundation (history's largest donor to cannabinoid research).





Our Radicle vision is a world where health and wellness products are...



"At its core, Radicle is a **Rebellion** against the status quo of healthcare and research and a **Movement** towards democratized, personalized consumer health products that have the potential to deliver well-being for all future generations."

Radicle Science Co-founders & Rebels With a Cause

*Objective evidence of safety and effectiveness

**By healthcare providers



© 2022 MJBiz, a division of Emerald X, ELC

A Radicle solution


Data transforms health and wellness products into democratized precision solutions

10x cheaper and faster studies that are:

- 1. Virtual
- 2. Direct to consumer


ER

- 3. Large Scale
- 4. Intentionally Heterogeneous



Radicle ACES

Advancing CBD Education & Science







RESEARCH TEAM

- Principal Investigator
 - Kelsey Laird, PhD (Adjunct Faculty, California Institute of Integral Studies)
- Co-Investigators
 - Jessica Saleska, PhD/MPH (Director of Research, Radicle Science)
 - Emily Pauli, PharmD (Chief Research Officer, Radicle Science)
 - Jeff Chen, MD/MBA (Co-founder & CEO, Radicle Science)



- Collaborators:
 - Miroslav Backonja, MD (Clinical Professor, University of Washington)
 - Chris Colwell, PhD (Professor, UCLA)
 - Derek Loewy, PhD (Director of Behavioral Sleep Medicine at Scripps Clinic Sleep Center)
 - Ethan Russo, MD (Founder and CEO of CReDO Science)
 - Kate Taylor, PhD (Associate Professor, UCLA)
 - Jill Waalen, MD/MPH (Co-Director of Biostatistics at Scripps Research)



STUDY DESIGN

- 4-week, open-label
- Randomized with a waitlist control arm
- 2820 participants aged 21 and older, with prior symptoms of anxiety, sleep disturbance, and/or chronic pain
- 2704 randomized across 13 CBD products (208 each)
- 296 randomized to a waitlist control
- <u>Primary Objective</u>: participants' change in well-being from baseline, compared to a waitlist control
- <u>Secondary Objective</u>: participants' change in pain, sleep disturbance, and/or feelings of anxiety from baseline, compared to a waitlist control

THE EMERALD CONFERENCE Produced by MIBizScience

Radicle Timeline

- Q1 2021
 - o Study design
- Q2 2021
 - Study build on tech platform
 - o IRB

• Q3 2021

- Recruitment
- Product shipment
- o Study launch
- Study completion
- Q4 2021
 - Personalized Health Reports sent to all participants
- e 2022 M. Biz, a division of Omerced X. LLC Brand Reports sent to all brands

THE EMERALD CONFERENCE

Produced by MJBizScience

Participating Products






Study products

- Products took the form of capsules, fast-melt tablets, tinctures, softgels, gummies, and an oral spray
- Products varied by CBD dosage, mode of absorption and spectrum


*N=2820




THE EMERALD CONFERENCE Produced by MIBizScience

Demographics

Participants resided in all 50 states, though most live in California, Texas and Florida



Most (94%) of the participants were female while 6% were Male



The majority (81.5%) of participants in the study were White, followed by Black (8.7%), Asian or Pacific Islander (3.1%), and other races (6.7%)



Methods

Linear mixed models to compare key outcomes for:


- (1) Each product vs. waitlist control
- (2) Product characteristics
 - spectrum and CBD dose
- (3) Participant characteristics
 - evaluating three-way interaction between CBD x time x [sex/age/prior CBD use]

THE EMERALD CONFERENCE Produced by MIBizScience

Impact on well-being & anxiety

Taking any CBD product led to significant improvements across all health outcomes, relative to waitlist control.

These effects were significant at every time point of the study (i.e., at weeks 1, 2, 3 and 4).*



© 2022 M/Biz, a division of Emerald X, LLC

*Based on linear mixed models (random intercepts with unstructured residual errors) comparing the effects of taking any CBD product (pooled) to waitlist control, and comparing each CBD product (individually) to waitlist control. We corrected for multiple comparisons using Bonferroni correction.

THE EMERALD CONFERENCE Produced by MIBizScience

Impact on sleep & pain

Taking any CBD product led to significant improvements across all health outcomes, relative to waitlist control.

These effects were significant at every time point of the study (i.e., at weeks 1, 2, 3 and 4).*



© 2022 M/Biz, a division of Emerald X, LLC

*Based on linear mixed models (random intercepts with unstructured residual errors) comparing the effects of taking any CBD product (pooled) to waitlist control, and comparing each CBD product (individually) to waitlist control. We corrected for multiple comparisons using Bonferroni correction.




Outcomes

- Largest improvements observed in the **first week** of using product
- Participants experienced a 71% improvement in their well-being score, on average
- 63% of participants with anxiety experienced a clinically meaningful improvement
- **61%** of participants with sleep difficulties experienced a clinically meaningful improvement
- 47% of participants with pain experienced a clinically meaningful improvement

THE EMERALD CONFERENCE Produced by MIBIZSCIENCE

Product characteristics & wellbeing improvement



Spectrum Broad Full Isolate

> Certain lower dosage groups (1-15 mg CBD per serving) outperformed higher dosage groups in well-being

No significant differences by spectrum


Average Who-5 Well-being score at week 4 by daily CBD dose. Color shows details about spectrum

THE EMERALD CONFERENCE

Product characteristics & anxiety

Produced by MJBizScience

improvement




Certain lower dosage groups (1-15 mg CBD per serving) outperformed higher dosage groups in well-being

No significant differences by spectrum

Average GAD-7 Anxiety score at week 4 by daily CBD dose. Color shows details about spectrum.



Product characteristics & sleep disturbance improvement




No significant differences by CBD dose or spectrum for sleep quality

THE EMERALD CONFERENCE

Product characteristics & pain

Produced by MJBizScience

improvement



Certain lower dosage groups (1-15 mg CBD per serving) outperformed higher dosage groups in well-being

No significant differences by spectrum

Average PEG score at week 4 by daily CBD dose. Color shows details about spectrum.



Key Findings

- Taking any CBD product led to significant improvement across all health outcomes, relative to waitlist control
- Side effects were rare (~10%) and mild
- There were **no** significant differences by participant sex, age or prior CBD use
- There were **no** significant differences by CBD spectrum
- Lower doses of CBD per serving (1 to 15 mg) often outperformed higher doses for the improvement of well-being, anxiety and pain



What types of people experienced the greatest improvements?

- There were no significant differences in the effect of taking any CBD product between males and females
- There were no significant differences in the effect of taking any CBD product between naive, moderate and experienced CBD users
- There were no significant differences in the effect of taking any CBD product between different age groups

THE EMERALD CONFERENCE Produced by MJBizScience

Side effects

Approximately 10% of participants reported any side effect from taking a CBD product

 Gas/ flatuleance
 36

 Headaches
 36

 Diarrhea
 32

 Bloating
 32

 tal fog/ forgetful
 30

 burn/ chest pain
 29

 Nausea
 25

42

Mental fog/ forgetful Heartburn/chest pain Trouble falling or staying as leep 24 24 Anxietv Irritability or depressed mood 22 Increased appetite 20 Fatigue 20 Reduced appetite 18 Jittery/twitching 15 Itchiness 14 Muscle aches 12 Skin rash b Sore throat 2 Dry mouth 2 Mouth numbness 1 Elevated heart rate 1 Lower back pain 1

Loss of taste

Indigestion

1

5

10

15

20

25

30

35

40

45

0



Caveats

- Cannot disentangle placebo effects
- Female gender skew of study participants
- Limited comparability between products by single characteristic
 - Multifactorial diversity of attributes
 - Suggestion serving
 - Form factor
 - Formulation



What does this all mean?

Results of this study suggest that comparable populations taking these CBD products could experience **significant improvements** in well-being, anxiety, sleep quality and pain **in just 4 weeks**.

They also suggest that these products have a **favorable safety profile**, as few side effects were reported (most of which were mild).

Finally, for the products in this study, our results suggest that effects may vary based on the amount of **CBD per serving**.



Produced by MJBizScience

RADICLE SCIENCE

Thank You!

For more information: jeff@radiclescience.com Cofounder/CEO

© 2022 M/Biz, a division of Emerald X, LL



We want to hear from you!

Scan the QR code below to provide your feedback on the presentation.

